Chemical Structure (Nuplazid 01)
Chemical structure of pimavanserin tartrate, the active ingredient in NUPLAZID capsules.*
Nuplazid Tablet, Coated
Product Images NDC 63090-100
8 FDA label images from Acadia Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Nuplazid (NDC 63090-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Acadia Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Nuplazid 02)
A forest plot chart illustrating pharmacokinetic (PK) changes in area under the curve (AUC) and maximum concentration (Cmax) with 90% confidence intervals in populations with varying degrees of renal impairment (severe and ESRD) and hepatic impairment (mild, moderate, severe). The x-axis shows fold change relative to reference from 0.5 to 4.*
Figure 2 (Nuplazid 03)
A pharmacokinetic (PK) chart showing fold change and 90% confidence intervals for AUC and Cmax of dopaminergic agent carbidopa/levodopa and CYP3A4 substrate midazolam after 18 and 38 days of NUPLAZID treatment, relative to reference doses. The x-axis represents change relative to reference from 0.5 to 2.*
Figure 3 (Nuplazid 04)
A line graph showing change from baseline (LSM ± SE) over six study weeks for 34 mg NUPLAZID capsules compared to placebo. The x-axis represents study weeks (0, 2, 4, 6), and the y-axis represents change from baseline, with 34 mg NUPLAZID showing a greater decrease over time compared to placebo.*
Figure 4 (Nuplazid 05)
A bar chart comparing the percent of patients showing various levels of improvement, including worsened or no change, between 34 mg NUPLAZID and placebo groups. The x-axis represents different categories of response improvement, while the y-axis shows the percent of patients. The 34 mg NUPLAZID group consistently shows higher response rates across all improvement categories compared to placebo.*
Figure 5 (Nuplazid 06)
A bar graph comparing the effect of 34 mg NUPLAZID (pimavanserin tartrate) versus placebo on a measured outcome with improvement and worsening on the vertical axis. The graph shows mean change values for 92 subjects on NUPLAZID and 88 on placebo, with bars indicating improvement for both groups.*
Principal Display Panel (60 Tablets Bottle Label)
NUPLAZID 34 mg capsules packaging label by Acadia Pharmaceuticals Inc. The label indicates oral capsules containing 34 mg of pimavanserin per capsule, with a package size of 30 capsules. It includes storage and dosage information as well as barcode and manufacturer details.*
Nuplazid 08
NUPLAZID 10 mg tablets label for pimavanserin capsules by Acadia Pharmaceuticals Inc., featuring dosage strength of 10 mg per tablet. The label includes storage instructions, barcode, and quantity of 30 tablets. The NDC number 63090-100-30 is displayed prominently, along with usage and safety advisories.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
